Cargando…

Cutaneous Vasculitis with Gut Involvement During Secukinumab Treatment for Psoriatic Arthritis

Detalles Bibliográficos
Autores principales:	CHELLI, Clara, LOGET, Jeffrey, VANHAECKE, Clélia, DURLACH, Anne, GAGNEUX-LEMOUSSU, Laurence, SORIANO, Clothilde, VIGUIER, Manuelle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Society for Publication of Acta Dermato-Venereologica 2020
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9128929/ https://www.ncbi.nlm.nih.gov/pubmed/32115666 http://dx.doi.org/10.2340/00015555-3435

Ejemplares similares

Multifocal Diffuse Dermal Angiomatosis: A Reflection of High Cardiovascular Risk
por: DIAZ, Emmanuelle, et al.
Publicado: (2020)

Secukinumab for ankylosing spondylitis and psoriatic arthritis
por: Lubrano, Ennio, et al.
Publicado: (2016)

Secukinumab: A Review in Psoriatic Arthritis
por: Blair, Hannah A.
Publicado: (2021)

A Review of the Use of Secukinumab for Psoriatic Arthritis
por: Patel, Nupur U., et al.
Publicado: (2017)

Correction to: Secukinumab: A Review in Psoriatic Arthritis
por: Blair, Hannah A.
Publicado: (2021)

Sarcoidosis manifesting during treatment with secukinumab for psoriatic arthritis
por: Kirby, Colm, et al.
Publicado: (2021)

Multicenter Study of Secukinumab Survival and Safety in Spondyloarthritis and Psoriatic Arthritis: SEcukinumab in Cantabria and ASTURias Study
por: Alonso, Sara, et al.
Publicado: (2021)

Erratum to: Secukinumab: A New Treatment Option for Psoriatic Arthritis
por: Mease, Philip, et al.
Publicado: (2016)

Cost Effectiveness of Secukinumab for the Treatment of Active Psoriatic Arthritis in the UK
por: Buchanan, Vanessa, et al.
Publicado: (2018)

Association of Secukinumab Treatment With Tuberculosis Reactivation in Patients With Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis
por: Elewski, Boni E., et al.
Publicado: (2021)

Efficacy and Safety of Secukinumab in Chronic Plaque Psoriasis and Psoriatic Arthritis Therapy
por: Gisondi, Paolo, et al.
Publicado: (2014)

Real-world data on secukinumab use for psoriatic arthritis and ankylosing spondylitis
por: Elliott, Ashley, et al.
Publicado: (2019)

Real-world effectiveness and persistence of secukinumab in the treatment of patients with psoriatic arthritis
por: Alegre-Sancho, Juan José, et al.
Publicado: (2023)

Recalcitrant annular pustular psoriasis associated with psoriatic arthritis successfully treated with secukinumab
por: Herrero-Moyano, María, et al.
Publicado: (2018)

Real Life Efficacy and Safety of Secukinumab in Biologic-Experienced Patients With Psoriatic Arthritis
por: Klavdianou, Kalliopi, et al.
Publicado: (2020)

New-Onset Collagenous Colitis in a Patient With Psoriatic Arthritis: Can It Be Secukinumab?
por: Obeidat, Adham E, et al.
Publicado: (2021)

Safety and effectiveness of secukinumab in psoriasis vulgaris and psoriatic arthritis: Real‐world evidence in Japan
por: Fujita, Hideki, et al.
Publicado: (2020)

A Machine Learning Approach to Predict Remission in Patients With Psoriatic Arthritis on Treatment With Secukinumab
por: Venerito, Vincenzo, et al.
Publicado: (2022)

Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies
por: Coates, Laura C., et al.
Publicado: (2019)

Efficacy and safety of secukinumab in patients with psoriatic arthritis: A meta-analysis of different dosing regimens
por: Zhang, Kai-Lin, et al.
Publicado: (2021)

Efficacy and safety of secukinumab over 52 weeks in Chinese psoriasis patients with concomitant psoriatic arthritis
por: Cai, Lin, et al.
Publicado: (2021)

Secukinumab Efficacy in Psoriatic Arthritis: Machine Learning and Meta-analysis of Four Phase 3 Trials
por: Gottlieb, Alice B., et al.
Publicado: (2021)

Impact of hyperuricaemia on patients with psoriatic arthritis treated with secukinumab in the FUTURE 2–5 and MAXIMISE studies
por: Felten, Renaud, et al.
Publicado: (2023)

Effects of TNF-α inhibition versus secukinumab on active ultrasound-confirmed enthesitis in psoriatic arthritis
por: Elliott, Ashley, et al.
Publicado: (2023)

Impact of Bariatric Surgery on Hidradenitis Suppurativa
por: CANARD, Clothilde, et al.
Publicado: (2021)

Changes in metabolic parameters in psoriatic patients treated with secukinumab
por: Wang, Hsuan Ning, et al.
Publicado: (2020)

Comparative Effectiveness of Adalimumab versus Secukinumab for the Treatment of Psoriatic Arthritis: A Matching-Adjusted Indirect Comparison
por: Strand, Vibeke, et al.
Publicado: (2017)

Vitiligo with Progressive Repigmentation during Secukinumab Treatment in a Patient with Psoriatic Arthritis: A Case Report
por: Giordano, Domenico, et al.
Publicado: (2021)

Drug Retention and Safety of Secukinumab in a Real-World Cohort of Ankylosing Spondylitis and Psoriatic Arthritis Patients
por: Moskal, Mateusz, et al.
Publicado: (2022)

Characteristics of Patients with Psoriatic Arthritis Receiving Secukinumab and Reasons for Initiation: A US Retrospective Medical Chart Review
por: Sunkureddi, Prashanth, et al.
Publicado: (2019)

Cost-effectiveness analysis of ixekizumab versus secukinumab in patients with psoriatic arthritis and concomitant moderate-to-severe psoriasis in Spain
por: Schweikert, Bernd, et al.
Publicado: (2020)

Successful secukinumab treatment of erythrodermic psoriasis and psoriatic arthritis concomitant with severe noninfectious uveitis: a case report
por: Lu, Jiajing, et al.
Publicado: (2020)

Clinically relevant patient clusters identified by machine learning from the clinical development programme of secukinumab in psoriatic arthritis
por: Pournara, Effie, et al.
Publicado: (2021)

A case of twins affected by psoriasis, psoriatic arthritis and autism: Five years of efficacious and safe treatment with Secukinumab
por: Bernardini, Nicoletta, et al.
Publicado: (2022)

Predictors of response to secukinumab in patients with psoriatic arthritis and axial manifestations: a post-hoc analysis of the MAXIMISE trial
por: Baraliakos, Xenofon, et al.
Publicado: (2022)

Le déconfinement de 2020 s’est-il accompagné d’un effet « boom » des infections sexuellement transmissibles ?
por: Singh, Tanya, et al.
Publicado: (2021)

A Case of Recalcitrant Psoriatic Arthritis to TNF Inhibitors Improved After Administration of Secukinumab, an IL-17A Inhibitor
por: Pelechas, Eleftherios, et al.
Publicado: (2017)

Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis
por: Kawalec, P., et al.
Publicado: (2017)

Cost-effectiveness analysis of secukinumab versus other biologics and apremilast in the treatment of active Psoriatic arthritis: a Finnish perspective
por: Purmonen, Timo, et al.
Publicado: (2018)

Effectiveness and safety of secukinumab in 608 patients with psoriatic arthritis in real life: a 24-month prospective, multicentre study
por: Ramonda, Roberta, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_870b7mt5cpfs2hrobm40b615nt